Skip to main content
. 2022 May 13;23:177. doi: 10.1186/s12859-022-04726-7

Fig. 8.

Fig. 8

Assessment of the predictive value of risk score for immunotherapeutic responses. A Kaplan–Meier curves for the OS of patients in the IMvirgor210 cohort. B The difference of the risk score among different anti-PD-L1 clinical response groups. C The proportion of patients responding to PD-L1 blockade therapy in the high-risk and low-risk groups. (CR: complete response, PR: partial response, SD: stable disease, PD: a progressive disease)